GlassScriptPhysician profile
Roshan Patel
NPI 1487117271
$1,358.37
in general payments reported to CMS, 2019-2025
25 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.74 · 2023: $172 · 2024: $439 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.96 | 2024-2025 | |
| Lilly USA, LLC | $121.43 | 2023-2025 | Mounjaro, Jardiance |
| Inspire Medical Systems, INC. | $113.68 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $109.61 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $106.35 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $85.05 | 2025 | Gemtesa |
| Pfizer INC. | $71.18 | 2024-2025 | |
| Dexcom, INC. | $68.65 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.06 | 2024 | Jardiance |
| Astellas Pharma US INC | $50.34 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $49.46 | 2024-2025 | |
| Amgen INC. | $49.13 | 2025 | Otezla, Repatha |
| Noven Therapeutics, LLC | $43.80 | 2024-2025 | Xelstrym |
| Exact Sciences Corporation | $41.40 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $34.21 | 2024 | Arexvy, Shingrix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $25.71 | 2024-2025 | Nexplanon |
| Novartis Pharmaceuticals Corporation | $23.74 | 2022 | |
| Corium, LLC | $22.38 | 2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.78 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $19.69 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $17.68 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $17.65 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $16.72 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $15.18 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $13.53 | 2025 | M-M-R II, Rotateq, Vaxelis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.